- 71% of pegcetacoplan-treated patients achieved LDH normalization vs. 15% of eculizumab-treated patients
- 73% of pegcetacoplan-treated patients achieved a clinically meaningful improvement in FACIT-fatigue score vs. 0% of eculizumab-treated patients
- Detailed results from positive head-to-head Phase 3 PEGASUS study in patients with paroxysmal nocturnal hemoglobinuria (PNH) presented in oral session at 25th Congress of the European Hematology Association
- NDA and MAA submissions planned in H2 2020. Conference call scheduled today at 8:30 a.m. ET
WALTHAM, Mass., June 12, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today presented detailed results from the Phase 3 PEGASUS study, which in January showed superiority (p